2026-02-17, 2:14:09 p.m.
REDWOOD CITY, Calif. — February 17, 2026 — Leads & Copy —
Coherus Oncology, Inc. (NASDAQ: CHRS) has announced the closing of an underwritten public offering of 28,600,000 shares of its common stock. The shares were sold at a public offering price of $1.75 per share, before underwriting discounts and commissions.
The gross proceeds to Coherus from the Offering were approximately $50.1 million, before deducting underwriting discounts and commissions and other offering expenses. All shares in the Offering were sold by the Company.
The Offering was led by new investors Janus Henderson Investors, HBM Healthcare Investments and Samsara BioCapital.
Coherus has granted the underwriters of the Offering a 30-day option to purchase up to an additional 4,290,000 shares of common stock at the public offering price, less the underwriting discounts and commissions, solely for the purpose of covering over-allotments.
Denny Lanfear, Chairman and Chief Executive Officer, stated that over the last two years the company has strengthened its balance sheet, reduced its debt by over 80%, and transformed Coherus from a biosimilar company to a clinical-stage Biotech focused on innovative oncology. Lanfear said that with this financing, Coherus is making further progress in rebuilding its capitalization table to support its expanding clinical development programs and upcoming data readouts, while funding commercial efforts to increase market penetration and revenue generation. He added that the company believes it is well positioned for future success.
Coherus intends to use the net proceeds from the Offering to support the ongoing commercialization of LOQTORZI® (toripalimab-tpzi), to continue clinical development of its product candidates, and for working capital and other general corporate purposes.
TD Cowen, Guggenheim Securities, and Oppenheimer & Co. acted as the joint bookrunners for the Offering.
The securities described were offered by Coherus pursuant to an effective shelf registration statement on Form S-3 (File No. 333-291520) that was previously filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 13, 2025. The Offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement.
A prospectus supplement and accompanying prospectus relating to and describing the terms of the Offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to these securities may be obtained by request from: TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or Oppenheimer & Co. Inc. Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY 10004, by telephone at (212) 667-8055, or by email at EquityProspectus@opco.com.
Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, prostate, head & neck, colorectal and other cancers. The Company’s strategy is to grow sales of LOQTORZI in R/M nasopharyngeal carcinoma and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as through its partners.
Coherus’ innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and enhance outcomes for patients with cancer. Tagmokitug is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b/2a studies in patients with advanced solid tumors, including head and neck squamous cell carcinoma, colorectal cancer, gastric cancer, and esophageal cancer. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first-line hepatocellular carcinoma.
LOQTORZI® is a registered trademark of Coherus Oncology, Inc.
©2026 Coherus Oncology, Inc. All rights reserved.
Source: Coherus Oncology, Inc.
